Immunization with a plasmid encoding a modified hepatitis B surface antigen carrying the receptor binding site for...

Area of Science:

• Immunology
• Vaccinology
• Hepatitis B Research

Background:

• Hepatitis B virus (HBV) poses a significant global health challenge.
• Current prophylactic and therapeutic strategies for HBV infection require enhancement.
• The HBV surface antigen (HBsAg) is a key target for immune interventions.

Purpose of the Study:

• To evaluate the immunogenicity and efficacy of a novel DNA vaccine encoding a modified HBsAg.
• To assess the potential of this genetic vaccine for both prophylactic and therapeutic applications against HBV.

Main Methods:

• Intramuscular injection of a plasmid encoding a modified HBsAg in C57BL/6 mice.
• Characterization of humoral and cytotoxic T-lymphocyte (CTL) responses post-vaccination.
• Assessment of immune response and HBsAg clearance in HBsAg-transgenic mice.

Main Results:

• A single DNA injection induced high titers of anti-HBs and anti-preS1 antibodies.
• Strong HBV-specific CTL responses were observed in immunized mice.
• In HBsAg-transgenic mice, vaccination led to clearance of circulating HBsAg and antibody production.

Conclusions:

• The modified HBsAg DNA vaccine elicits robust humoral and cellular immunity.
• The vaccine demonstrates potential for clearing HBsAg and may be effective against chronic HBV carriers.
• This genetic vaccine holds promise for prophylactic and therapeutic use against hepatitis B.